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Abstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-
like peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin 
secretion and inhibits glucagon secretion, which results in lowering of glucose levels and 
improvement of the glycemic control in patients with type 2 diabetes. This review summa-
rizes experiences with DPP-4 inhibition in the treatment of type 2 diabetes, with a focus on 
sitagliptin. Sitagliptin has in several clinical studies been shown to improve metabolic control 
in type 2 diabetes, both when used as monotherapy and when used in combination with met-
formin, sulfonylurea, thiazolidinediones or insulin. The reduction in HbA1c is ≈0.6% to 1.0% 
from baseline levels of 7.5% to 8.7% over 6 to 12 months therapy. Sitagliptin has a favorable 
safety profile, is highly tolerable, and there is a minimal risk of hypoglycemia. Furthermore, 
sitagliptin is body weight neutral or induces a slight body weight reduction. Sitagliptin may be 
used in the early stages of type 2 diabetes in combination with metformin or other treatments 
in subjects with inadequate glycemic control on these treatments alone. Sitagliptin may also be 
used in monotherapy and, finally, sitagliptin may be used in combination with insulin in more 
advanced stages of the disease.
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Introduction
Hyperglycemia is a key factor underlying complications of type 2 diabetes, and, there-
fore, reducing hyperglycemia is a critical aim of treatment of the disease. Improving 
hyperglycemia has thus been shown to reduce the risk of microvascular complications 
and may also reduce macrovascular complications.1,2 The basis for treatment is lifestyle 
changes with increased physical activity and dietary modifications. If these treatments 
are not sufficient, pharmacological treatment with metformin is recommended.3 How-
ever, due to the progressive nature of the disease, additional pharmacological treatment 
is often required. Several options exist: sulfonylureas, thiazolidinediones, meglitinides, 
α-glucosidase inhibitors and insulin.3,4 There are, however, limitations with these 
pharmacological treatments, such that even with aggressive treatment using these 
approaches, glycemic control often deteriorates. Furthermore, current therapy is often 
associated with adverse events. These adverse events include hypoglycemia with sulfo-
nylureas and insulin, gastrointestinal discomfort with biguanides (such as metformin), 
and increased body weight, edema and cardiac insufficiency with thiazolidinediones.5–8 
Furthermore, the current therapies do not target all pathophysiological aspects of type 
2 diabetes. Thus, dysregulation of glucose metabolism in type 2 diabetes is caused by 
a combination of insulin resistance, impaired insulin secretion, augmented glucagon Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 32
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secretion and reduced β-cell mass.9–12 Whereas insulin 
resistance is treated by biguanides and thiazolidinediones, 
and insulin secretion is treated by sulfonylureas, no therapy 
treats the hypersecretion of glucagon and the reduced β-cell 
mass. There are thus several unmet needs in the treatment 
of diabetes which urge the development of novel treatment.
Recently, several new approaches have emerged to 
meet these challenges. These novel therapies include the 
amylin analog pramlintide and the GLP-1 receptor ago-
nists, including exenatide and liraglutide.13–15 Another novel 
class of compounds is inhibitors of the enzyme dipeptidyl 
  peptidase-4 (DPP-4). The DPP-4 inhibitors, which prevent 
the inactivation of the incretin hormones glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), increase the endogenous concentrations 
of these hormones which prolongs their actions and improves 
  glycemia.16–20 Several DPP-4 inhibitors have been developed 
and are in various stages of clinical development. Sitagliptin, 
vildagliptin and saxagliptin are approved for use in several 
countries.20 This article reviews evidence for clinical use of 
DPP-4 inhibitors, with a focus on sitagliptin.
Incretin-based therapy
GLP-1 is released from the gut following meal ingestion 
and GLP-1 in turn stimulates insulin secretion and inhibits 
glucagon secretion, which reduces glucose levels.16,17 GLP-1 
is, however, rapidly inactivated by the enzyme DPP-4, which 
cleaves the two N-terminal amino acids of the hormone 
making it largely inactive.16 This process is efficient; the 
half-life of active GLP-1 is less than 2 minutes. Inhibition 
of DPP-4 prevents therefore the rapid inactivation of GLP-1. 
A major mechanism underlying the antidiabetic action of 
the DPP-4 inhibitors is thus the increased concentrations of 
active GLP-1 as has been demonstrated by vildagliptin fol-
lowing meal ingestion.21 As a consequence, DPP-4 inhibition 
increases insulin secretion and inhibits glucagon secretion, 
which results in inhibition of hepatic glucose production, 
as demonstrated for vildagliptin.21–23 These actions reduce 
both fasting and prandial glucose levels and the 24-hour 
glucose profile, as has been shown for NVP-DPP728 and 
sitagliptin.24,25 Rodent studies have also shown that DPP-4 
inhibitors (vildagliptin and sitagliptin) increase islet mass 
and normalize islet cell topography in diabetes models in 
mice.26,27 This would suggest that DPP-4 inhibition targets 
the important islet dysfunctions in type 2 diabetes. It should 
be emphasized, however, that no evidence of increased β-cell 
mass by DPP-4 inhibitors exists in humans.
DPP-4 inhibition has been shown to be efficient in 
improving glycemia both as monotherapy and as add-on to 
metformin, sulfonylurea and thiazolidinediones in subjects 
with inadequate glycemic control. DPP-4 inhibition has also 
been shown to be safe, highly tolerated and body-weight 
neutral.18–20 In fact, DPP-4 inhibition meets several of the 
challenges of the treatment of today – it improves glycemia 
with little risk for hypoglycemia, it does not increase body 
weight, it is safe with very little risk for adverse events, and, 
due to its targeting of the key islet defects, it has the potential 
to modify the disease process.
Sitagliptin – pharmacokinetics  
and mechanisms of action
Structure and pharmacokinetics
Sitagliptin is a triazolopiperazine derivative (Figure 1).10 
It is orally active and it selectively and reversibly inhibits 
DPP-4 compared to inhibition of other members of the DPP 
family. Thus, in vitro studies have shown that at 18 nmol/L, 
sitagliptin inhibits DPP-4 by 50% whereas 48 µmol/L is 
required to inhibit DPP-8 by 50% and 100 µmol/L is 
required to inhibit DPP-9 by 50%28 The pharmacokinetics 
of sitagliptin have been examined in both healthy subjects29 
and in subjects with type 2 diabetes30 with no difference 
between these groups. Sitagliptin is rapidly absorbed after 
oral ingestion with an 87% bioavailability after intake of a 
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single 100 mg tablet.31 Cmax is observed within 1 to 2 hours 
and the half-life of the compound is ≈12 hours.31 Sitagliptin 
is minimally metabolized and ≈80% of the compound is 
excreted unchanged in the urine.32 Renal excretion is achieved 
through a combination of active secretion and glomerular 
filtration.29 Renal insufficiency increases circulating levels 
of sitagliptin in that plasma levels of sitagliptin are increased 
by 2-fold in patients with moderate renal impairment (creati-
nine clearance 30–50 mL/min) and by 4-fold in patients with 
severe renal impairment (creatinine clearance 30 mL/min), 
making dose adjustements recommended in these patients.33 
Hepatic insufficiency, obesity and old age do not seem to alter 
the pharmacokinetics of sitagliptin and no drug interactions 
have been observed for the compound.
Mechanisms of action
Sitagliptin rapidly inhibits DPP-4 after oral ingestion, and 
within 1 hour, DPP-4 activity, as determined in plasma, is 
inhibited by more than 90%.30 The duration of DPP-4 inhibi-
tion is such that the drug can be dosed once daily. The inhi-
bition of DPP-4 activity is dose-dependent and is sustained 
after multiple dosages, as demonstrated in studies up to 28 
days.30,33,34 Active GIP and GLP-1 levels are increased by 
sitagliptin by approximately 2- to 3-fold after meal inges-
tion or oral glucose.30,33,34 This results in increased insulin 
secretion as judged from increased insulinogenic index35–40 
and the homeostasis model of assessment of β-cell function 
(HOMA-β).36–46 Improved β-cell function is also evident 
from reduced proinsulin to insulin ratio.38,41–44,47 Sitagliptin 
also reduces glucagon levels,25,30 although this needs to be 
examined in more detail. The improved islet function by sita-
gliptin results in reduction of both fasting glucose and prandial 
glucose as revealed in different studies in subjects with type 2 
diabetes.25,36,48,49 In fact, the entire 24-hour glucose profile is 
reduced by sitagliptin, as is evident from a study examining 
addition of sitagliptin to ongoing metformin therapy compared 
to metformin treatment alone (Figure 2).25
Sitagliptin – clinical effects  
in monotherapy
Placebo-controlled studies
Sitagliptin was initially evaluated as monotherapy for 12 weeks 
in dose-findings studies in drug-naïve patients with type 2 
diabetes. At the dose of 100 mg, hemoglobin A1c (HbA1c) 
was reduced by sitagliptin by 0.6% from a baseline of 7.7% 
in one study comprising 555 subjects50 and by 0.8% from a 
baseline of 7.8% in another study of 743 subjects.45 A subse-
quent placebo-controlled, multi-center 18-week study in 521 
patients showed that sitagliptin at 100 mg or 200 mg once 
daily reduced HbA1c by 0.6% and 0.5%, respectively, from a 
baseline of 8.1%42 and a 24-week study using sitagliptin at 100 
mg or 200 mg daily in drug-naïve patients with a mean baseline 
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Figure 2 24-hour plasma glucose profile in patients with type 2 diabetes after four weeks treatment with sitagliptin (100 mg daily) added to ongoing treatment with 
  metformin compared to patients continued with metformin alone. Reproduced with permission from Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl 
peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabet Obes Metab. 2007; 9:186–193.25 Copyright © 2007 
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HbA1c of 8.0% (n = 741) showed a reduction of 0.8% and 0.9%, 
respectively.41 The improved glycemia during monotherapy 
with sitagliptin is sustained over at least 2 years, as shown 
in a 52-week study with an open label extension for another 
52 weeks: sitagliptin at 100 mg had after 2 years reduced HbA1c 
by 0.7% from a baseline of 7.5%.51 Sitagliptin has also been 
shown to efficiently improve glycemic control when used in 
monotherapy in a study comprising 530 Asian patients. Thus, 
one study showed that sitagliptin at 100 mg daily reduced 
HbA1c by 1.4% in Indians, by 1.4% in Koreans and by 0.7% 
in Chinese subjects with type 2 diabetes from baseline levels 
of 8.7% during 18 weeks treatment.35 Furthermore, in a study 
in 151 Japanese patients, sitagliptin at 100 mg daily reduced 
HbA1c by 0.7% from a baseline of 7.5% over a study period 
of 12 weeks in subjects with type 2 diabetes.36
Since sitagliptin is cleared by the kidney, dose adjust-
ments are required in subjects with moderate or severe renal 
insufficiency. One study examined the 54-week efficacy and 
safety of sitagliptin as monotherapy in subjects with type 2 
diabetes with moderate (dose 50 mg daily) or severe (dose 
25 mg daily) renal insufficiency. Mean baseline HbA1c was 
7.7% and sitagliptin reduced HbA1c by 0.7%, ie, similar to 
those in other studies.52 Furthermore, sitagliptin was safe 
and well tolerated in the subjects with renal insufficiency, 
with a lower risk of hypoglycemia relative to glipizide and 
with weight loss compared with weight gain with glipizide. 
Another study has examined the influence of sitagliptin in 
elderly patients. In this placebo-controlled study of 123 
patients with type 2 diabetes above 65 years of age, sita-
gliptin at 100 mg over 24 weeks reduced HbA1c by 0.7% from 
a baseline of 7.8%.53 Sitagliptin was well tolerated in the 
elderly with low degree of adverse events and hypoglycemia 
occurring only in one subject, compared to two subjects 
treated with placebo.
Sitagliptin – clinical effects  
when used in combination  
with metformin
Add-on to ongoing metformin
Sitagliptin has been shown to improve glycemic control when 
added to metformin in subjects with type 2 diabetes who are 
inadequately controlled when treated with metformin alone. 
One study showed that in patients with ongoing metformin 
treatment (n = 701) with a mean baseline HbA1c of 8.0%, 
sitagliptin at 100 mg daily during 24 weeks, reduced HbA1c by 
0.7% when compared to subjects who maintained treatment 
with metformin alone.44 Sitagliptin progressively reduced 
HbA1c levels during the first 12 weeks of treatment, and a 
sustained level was established thereafter. Also in Japanese 
patients, sitagliptin improves glycemic control when added 
to ongoing metformin treatment; the placebo-adjusted reduc-
tion in HbA1c by sitagliptin was 0.7%; baseline HbA1c was 
7.8%.37
Comparison with active comparator
One study compared the effect of sitagliptin (100 mg daily) 
with that of glipizide (up to 20 mg daily) when added to 
  ongoing treatment with metformin for a study period of 
52 weeks in a total of 1172 patients with type 2 diabetes with 
a mean baseline HbA1c of 7.5%.54 HbA1c was reduced simi-
larly by 0.7% in both groups (Figure 3). Sitagliptin (100 mg 
once daily) has also been compared with rosiglitazone (8 mg 
daily) when added to ongoing metformin in subjects with 
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inadequate glycemic control with metformin alone (mean 
HbA1c 7.7%; n = 273). After 18 weeks, HbA1c was reduced 
by 0.7% by sitagliptin and by 0.8% by rosiglitazone; the 
difference was not significant.55
Initial combination with metformin
One study has examined the initial combination of sitagliptin 
(100 mg daily) and metformin (1 or 2 g daily) compared to 
monotherapy treatment with sitagliptin or metformin alone 
for 24 weeks (n = 1091) in subjects with mean baseline HbA1c 
of 8.8%.43 Approximately half of the patients were drug-
naïve, whereas the other half had received oral agents before. 
There was a marked reduction in HbA1c after combination 
therapy (by 1.6% and 2.1% in the two groups differing in 
metformin dose, respectively).43 This study continued as an 
open-label extension for 104 weeks, thus providing 2-year 
data on sitagliptin when given in combination with metfor-
min. A total of 1091 patients were included at start of the 
study, 587 entered the extension and 402 were included in 
the final analysis. Reduction from baseline HbA1c was 1.4% 
and 1.7% in the two groups, respectively.51
Sitagliptin – clinical effects in 
combination with agents other 
than metformin
Combination with pioglitazone
Sitagliptin has been evaluated as add-on to ongoing treatment 
with pioglitazone in one placebo-controlled, 6-month study.47 
The study evaluated addition of sitagliptin (100 mg daily) to 
pioglitazone at 30 or 45 mg daily versus continuation with 
pioglitazone alone in patients with a mean baseline HbA1c of 
8.0% (n = 353). Sitagliptin reduced HbA1c by 0.7% versus 
pioglitazone alone.47 Similar results of improved glycemic 
control when sitagliptin was added to ongoing pioglitazone 
treatment were also demonstrated in Japanese patients.39
Combination with glimepiride
Sitagliptin has as well been evaluated as add-on to ongoing 
treatment with glimepiride in a 6-month study of 441 patients 
with a mean baseline HbA1c of 8.3%. Sitagliptin (100 mg 
daily) reduced HbA1c by 0.7% when adjusted for changes in 
the group continuing with glimepiride alone.46
Combination with insulin
One study evaluated the influence of sitagliptin (100 mg 
daily) when added to ongoing insulin therapy in a total of 617 
patients with type 2 diabetes.56 Mean baseline HbA1c was 8.7% 
and following addition of sitagliptin to the ongoing insulin 
therapy, HbA1c was reduced by 0.6% versus no change (0.0%) 
in patients who continued with insulin treatment alone.
Sitagliptin – clinical effects  
when used in triple therapy
Combination with metformin  
and sulfonylurea
A 6-month study evaluated addition of sitagliptin (100 mg 
daily) to a total of 441 patients with ongoing treatment with 
the combination of metformin and glimepiride with a base-
line HbA1c of 8.3%.46 It was found that HbA1c was reduced 
by 0.9% by sitagliptin compared to ongoing therapy with 
metformin and glimepiride.
Combination with metformin  
and thiazolidinediones
One study has examined the effect of addition of sitagliptin 
(100 mg daily) to ongoing therapy with metformin in 
  combination with rosiglitazone in a total of 277 patients 
with type 2 diabetes with a mean baseline HbA1c of 8.8%.57 
The addition of sitagliptin reduced HbA1c by 0.9% versus a 
reduction by 0.2% in patients who continued on metformin 
and rosiglitazone.
Clinical effects  
of sitagliptin – summary
The clinical trials show efficient and sustained (up to 2 years) 
improvement of glycemic control of sitagliptin both in mono-
therapy and in combination with metformin, glimepiride, piogli-
tazone and insulin and also improved effect when used in triple 
therapy together with metformin plus glimepiride or metformin 
plus rosiglitazone. In general, HbA1c was reduced by sitagliptin 
by ≈0.6% to 1.0% from baseline levels of 7.5% to 8.8%. An 
active comparative study has shown similar effect as glipizide 
when added to metformin.54 The effect of sitagliptin seems to 
be similar to other DPP-4 inhibitors, although head-to-head-
studies have not been undertaken.41,44,46,47,58–69 Figure 4 shows 
the reduction in HbA1c during 24- to 26-week studies with four 
different DPP-4 inhibitors as monotherapy or in combination 
with metformin, a sulfonylurea or a thiazolidinedione. Initial 
HbA1c levels differed in the different studies; overall no clear 
difference between the various DPP-4 inhibitors is evident.
Sitagliptin – safety and tolerability
Adverse events
The extensive experience with DPP-4 inhibition that now 
exists in clinical trials shows high tolerability and safety. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 36
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This is evident from results in several studies with a number 
of different DPP-4 inhibitors, which show that the number 
of adverse events is not increased in study groups treated 
with DPP-4 inhibitors compared to placebo groups, and the 
drop out rates from studies due to adverse events are low. 
This is evident also for sitagliptin,35–57 and notably also in 
elderly patients53 and in patients with moderate or severe 
renal insufficiency.52 A meta-analysis has been published in 
regard to adverse events with sitagliptin in 12 large, double-
blind studies with durations from 18 weeks to 2 years.70 The 
meta-analysis comprised a total of 3415 patients treated 
with sitagliptin (100 mg daily) and 2724 controls, who 
were treated either with other antihyperglycemic agents or 
placebo. The overall incidence of adverse events in these 
studies was 63% in patients given sitagliptin versus 63% 
in controls, ie, the same degree of total number of events. 
Serious adverse events were also similar in the two groups 
(7%) as was the number of patients who discontinued 
therapy (35% vs 36%) or withdrew from the studies due to 
adverse events (3% vs 4%). Some adverse events occurred, 
however, during the treatment with sitagliptin, although 
the pattern differed between different studies. When used 
as add-on to metformin adverse events were absent more 
frequently with sitagliptin versus metformin alone. When 
used as initial combination with metformin or as add-on 
to thiazolidinedione, the most frequent adverse events 
occurring more commonly in the sitagliptin group were 
headache and upper respiratory tract infection (5%–6% 
vs 3%–5% with metformin or thiazolodinedione alone), 
and most frequent adverse events for sitagliptin when 
combined with sulfonylurea were hypoglycemia (12% vs 
2%), nasopharyngitis (6% vs 5%) and headache (6% vs 
2%). Furthermore, sitagliptin seems to be safe from a car-
diovascular point of view, since adverse events suggestive 
of cardiac disorders (such as acute coronary syndrome, 
acute myocardial infarction or angina pectoris) were absent 
more frequently in patients treated with sitagliptin versus 
comparators or placebo.70
Following the reports of acute pancreatitis in subjects 
treated with exenatide or sitagliptin, concern has been raised 
that incretin based therapy is associated with increased risk of 
acute pancreatitis. This is difficult to establish because there 
is a generalized increased risk of acute pancreatitis in patients 
with diabetes, obesity or hyperlipemia. A claims-based 
drug surveillance system has, however, shown that the risk 
for pancreatitis is not higher when patients are treated with 
sitagliptin (or exenatide) than when treated with metformin 
or sulfonylurea.71 Also a few serious hypersensitivity reac-
tions have been reported during treatment with sitagliptin. 
Therefore, although being extremely well tolerated in studies 
up to 2 years, long-term surveillance is of importance for the 
detection of potential adverse events that might occur at later 
stages or infrequently during treatment with sitagliptin.
Hypoglycemia
Hypoglycemia is rare (3%) during treatment with DPP-4 
inhibitors as monotherapy or in combination with metfor-
min or thiazolidinediones.35–38,41–45,47,53 The low degree of 
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hypoglycemia is especially seen when compared with the 
risk of hypoglycemia during treatment with sulfonylurea 
(Figure 4). This is explained by the glucose-dependency of 
the islet effects of GLP-1; hence when glucose levels are 
reduced the effects of GLP-1 in stimulating insulin secre-
tion and inhibiting glucagon secretion vanish. In contrast, 
hypoglycemia was shown to be more common when sita-
gliptin was added to ongoing glimepiride; the incidence 
of hypoglycemia was 12% versus 2% in the group given 
glimepiride alone.46 The potential risk for hypoglycemia 
when combining sitagliptin and sulfonylureas may be due 
to an uncoupling mechanism of sulfonylureas of the glu-
cose dependency of the islet actions by GLP-1.72 This risk 
needs, however, to be evaluated in more detail. If increased 
frequency of hypoglycemia when combining sitagliptin 
with a sulfonylurea is confirmed, a clinical consequence 
is that the dose of sitagliptin or sulfonylureas should be 
reduced when these are used in combination. Similarly, 
when combined with insulin, there was an increased risk 
for hypoglycemia by sitagliptin.56
In spite of the very low risk of hypoglycemia during 
treatment with DPP-4 inhibition, a concern might be that if 
hypoglycemia nevertheless evolves, DPP-4 inhibition might 
compromise the counterregulation, if it is associated with 
inhibition of glucagon secretion also under these conditions. 
A recent study addressed this by examining the glucagon 
response to hypoglycemia in patients treated with the DPP-
4 inhibitor vildagliptin.73 It was found that contrary to the 
inhibition of glucagon secretion after meal ingestion by vilda-
gliptin, ie, when glucose levels are elevated, the glucagon 
response to hypoglycemia was not inhibited.72 This preserved 
glucagon secretion during hypoglycemia in patients treated 
with vildagliptin suggests that DPP-4 inhibition prevents 
hypoglycemia. This prevention may be due to improved 
glucose sensing in the α-cells such that DPP-4 inhibition, 
through GLP-1, restores and improves the action of glucose 
on glucagon secretion, ie, it augments the inhibition of gluca-
gon secretion at high glucose but exaggerates the stimulation 
of glucagon secretion at low glucose. A similar study with 
sitagliptin is warranted to examine whether sitagliptin, like 
vildagliptin, would prevent hypoglycemia.
Sitagliptin – other potential effects
Body weight
Many studies show that sitagliptin is body weight   
neutral.41–47,51,54,57 Therefore, when compared to thiazolidine-
diones, sulfonylureas and insulin, DPP-4 inhibition shows 
advantage compared to the increase in body weight which 
is associated with these other treatments. This is clearly evi-
dent when compared with glipizide, which increased body 
weight, whereas sitagliptin was body weight neutral over a 
study period of 52 weeks (Figure 454).
Lipids
In clinical studies with sitagliptin, there has been either no 
significant change in lipids42,47 or small beneficial effects on 
blood lipids.44,45 The two studies reporting effects showed that 
when sitagliptin was added to metformin, total cholesterol 
was reduced by 3% to 6%, triglycerides were reduced by 
17%, non-high-density lipoptrotein (HDL)-cholesterol was 
reduced by 10% to 19% and HDL-cholesterol was increased 
by 2%.44,45 Potential long-term effects of sitagliptin on lipids 
remain to be established.
Sitagliptin – regulatory aspects
Sitagliptin (Januvia®; Merck) was approved by the Food 
and Drug Administration (FDA) in October 2006 and by 
the European Medicines Agency (EMEA) in April 2007. It 
is at present approved in 85 countries throughout the world. 
It is indicated for use as monotherapy and in combination 
therapy. As monotherapy, the indication in the US is as an 
adjunct to diet and exercise to improve glycemic control 
in patients with type 2 diabetes, whereas in the EU, it is 
indicated as monotherapy in patients who have inadequate 
glycemic control with diet and exercise and in whom metfor-
min is inappropriate due to contraindications or intolerance. 
Sitagliptin is also indicated, both in the US and in EU, in 
combination therapy with metformin, a sulfonylurea or a 
thiazolidinedione in patients who have inadequate control 
with these agents used as single agents plus diet and exercise. 
Recently, sitagliptin was also approved to be used in com-
bination with insulin. Sitagliptin is also indicated as triple 
therapy in combination with metformin plus a sulfonylurea 
or metformin plus a thiazolidinedione in patients who have 
inadequate glycemic control with the two agents.
The recommended dose for sitagliptin is 100 mg daily as 
a single tablet. When used as add-on to metformin or thia-
zolidinediones, the doses of these agents can be maintained, 
whereas when added to a sulfonylurea it is recommended that 
the dose of the sulfonylurea is reduced. Sitagliptin exists also 
as a combination tablet with metformin. The tablets contain 
50 mg sitagliptin and 850 mg metformin (Janumet®). The 
recommended dose of these tablets is twice daily, which is 
equivalent to 100 mg sitagliptin daily.
In the US the dose of sitagliptin is recommended to 
be lowered in subjects with renal insufficiency: 50 mg Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 38
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daily in moderate renal insufficiency (creatinine clearance 
30-50 mL/min), and 25 mg daily in severe renal insufficiency 
(creatinine clearance 30 mL/min). In the EU, sitagliptin is 
not recommended in subjects with renal insufficiency.
Conclusions and clinical  
positioning of sitagliptin
DPP-4 inhibition as a novel therapy of type 2 diabetes 
improves islet function due to the increased concentra-
tions of active GLP-1, which stimulates insulin secretion 
and inhibits glucagon secretion. Since these effects target 
main pathophysiologic defects in type 2 diabetes, DPP-4 
inhibition is a treatment targeting pathophysiologically 
relevant aspects of the disease. The therapy therefore holds 
the promises of improving basis of the disease and may 
therefore be the solution to several of the currently unmet 
needs for treatment of the disease. Clinical trials also show 
the efficacy of the strategy, and the safety profile shows low 
risk for adverse events or hypoglycemia. DPP-4 inhibition 
is therefore a novel and promising paradigm for treatment 
of type 2 diabetes.
Sitagliptin is a DPP-4 inhibitor which has shown good 
clinical effect in reducing glycemia both as monotherapy 
and in combination with other oral agents and with insulin. 
Sitagliptin may be of greatest value as add-on to ongoing 
metformin in patients with inadequate glycemic control 
when treated with metformin alone or as monotherapy in 
subjects in whom metformin is contraindicated or in subjects 
with adverse events from metformin. Initial combination 
with DPP-4 inhibitors and metformin in drug-naïve patients 
requiring pharmacological treatment for glycemic control, 
would be another place of the therapy. The reason for this is 
that sitagliptin improves pathophysiological defects which 
are seen early during the progression of diabetes, mainly 
the islet dysfunction, in association with safety and high 
tolerability. In particular, the occurrence of hypoglycemia 
is rare, which makes it of special interest in early stages as 
well as in elderly patients.
DPP-4 inhibition may be of greatest impact as add-on to 
metformin in patients with inadequate control of glycemia 
when treated with metformin alone. The clinician may in 
such a situation select between a DPP-4 inhibitor and a 
sulfonylurea. It is therefore of interest that when directly 
comparing sitagliptin versus glipizide when added to met-
formin in such patients, the reduction in HbA1c was the same 
over a 6 month but yet important differences existed.54 Thus, 
whereas glipizide increased body weight, sitagliptin reduced 
body weight, and whereas glipizide resulted in several events 
of hypoglycemia, this was rare with sitagliptin (Figure 454). 
A similar finding was recently reported also for vildagliptin 
after 1 year of treatment when added to metformin versus 
glimepiride.74 Hence, although long term comparisons are 
required, DPP-4 inhibition offers a better outcome than 
sulfonylurea when added to metformin over a duration of 
6 months to 1 year.
Sitagliptin may also be exchanged for sulfonylurea or 
thiazolidinediones in combination with metformin in subjects 
with intolerance to sulfonylurea or thiazolidindediones or 
with inadequate glycemic control with these combinations. 
This might also be a useful indication, considering the limita-
tion when using sulfonylureas or thiazolidinediones in terms 
of adverse events. Furthermore, DPP-4 inhibition has also 
an important place as add-on to sulfonylurea or thiazolidine-
diones in subjects with inadequate glycemic control when 
treated with these agents alone. A potential future combi-
nation is DPP-4 inhibition plus insulin, in more advanced 
stages of the disease. Hence, DPP-4 inhibition may be used 
both in early stages of the diseases, as monotherapy or in 
combination therapy, as well as in more advanced stages of 
the disease. This is in line with a recent algorithm for glyce-
mic control as stated by an American Association of Clini-
cal Endocrinologists/American College of Endocrinology 
Consensus Panel.75
The evidence for the beneficial effect of sitagliptin is 
its efficacy in improving glycemic control in studies over 
6 to 12 months in association with safety and low risk of 
adverse events. The long-term durability is now important 
to consider and of high importance for the future long-term 
value of this class of compounds. Whether sitagliptin may 
have additional beneficial effects on islet mass, as has been 
shown in rodents,26 remains to be established in humans.
In the clinical context, sitagliptin offers similar indica-
tion as the other DPP-4 inhibitors and the GLP-1 receptor 
agonists. Sitagliptin is very similar to the other DPP-4 
inhibitors on the market, vildagliptin and saxagliptin,20 and 
no long-term head-to-head study exists yet for these; it is 
therefore not possible yet to differentiate between them. Of 
the GLP-1 receptor agonists (GLP-1 mimetics), exenatide 
(Byetta®; Amylin and Eli Lilly) and liraglutide (Victoza®; 
Novo Nordisk) have been approved for therapy and several 
others are in clinical development, such as lixisenatide, 
albiglutide and taspoglutide. They are DPP-4 resistant com-
pounds which are based either on modification of the GLP-1 
molecule or based on the peptide exendin-4.76 The GLP-1 
mimetics are given through the subcutanoues route either 
once or twice daily or with longer intervals, such as once Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 39
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weekly. The efficacy of these compounds seems to be similar 
as that of the DPP-4 inhibitors. The main differences are that 
GLP-1 receptor agonists reduce body weight, whereas DPP-4 
inhibitors are body weight neutral; that GLP-1 mimetics are 
injectables, whereas DPP-4 inhibitors are active after oral 
administration; and that DPP-4 inhibitors are virtually free 
from adverse events, whereas GLP-1 mimetics are associated 
with nausea.
Sitagliptin, like the other DPP-4 inhibitors, has a higher 
cost per day of clinical use than sulfonylureass, which is an 
economic drawback for the DPP-4 inhibitors. However, a 
health economic model analysis has shown that addition of 
sitagliptin to metformin was cost saving compared to sul-
fonylurea or a thiazolidinedione in patients with inadequate 
glycemic control on metformin alone.77 Nevertheless, more 
studies are required on this issue.
For future studies, it is important to examine the 
durability and long-term effects and safety of sitagliptin. 
Studies are also required to compare the long-term effects 
in head-to-head studies with other DPP-4 inhibitors and 
with GLP-1 mimetics. Moreover, outcome studies in rela-
tion to co-morbidity, such as cardiovascular diseases, are 
required. Recently, Merck and Co. has initiated a clinical 
cardiovascular study with sitagliptin entitled “A randomized 
placebo controlled clinical trial to evaluate cardiovascular 
outcomes after treatment with sitagliptin in patients with 
type 2 diabetes mellitus and inadequate glycemic control 
on mono- or dual combination oral antihyperglycemic 
therapy” (TECOS).78 This is a long-term event-driven study 
with the primary objective of evaluating cardiovascular 
endpoints in high-risk populations; results are expected in 
2014. Furthermore, more mechanistic studies are required 
to establish more detailed information on how sitagliptin 
affects islet function, including effects on glucagon secre-
tion, and also effects on incretin hormone secretion and 
metabolism; most mechanistic studies on DPP-4 inhibition 
exist for vildagliptin.79 Studies directed at establishing poten-
tial contribution of the incretin hormone GIP, the level of 
which also is increased by DPP-4 inhibition. Finally, since 
sitagliptin relies on incretins which are released after meal 
ingestion, it is important to study their effects in relation 
to ingestion of various meal ingredients, since it is known 
that macronutrients have different effects on the release and 
concentrations of incretin hormones.80 Therefore, although 
much information exists on clinical effects and mechanisms 
of DPP-4 inhibition, more information is required for a fuller 
understanding of this promising concept to treat subjects 
with type 2 diabetes.
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